Table 2.
Variable | Reference | Level | OR (95 % CI) | p value(1) | p value(2) |
---|---|---|---|---|---|
Race | African American | European American | 1.4 (0.79–2.46) | 0.2457 | 0.2457 |
Age | 1 (1–1.01) | 0.5543 | |||
BMI | 24.9 or < | 25–29.9 | 1.61 (0.76–3.42) | 0.2140 | 0.4615 |
24.9 or < | 30 or > | 1.26 (0.63–2.53) | 0.5122 | ||
Age | 1 (0.98–1.02) | 0.8812 | |||
Metastasis | Negative | Positive | 2.37 (0.21–26.56) | 0.4847 | 0.4847 |
Tumor size | TIS/1/2 | 3/4 | 0.45 (0.22–0.92) | 0.0282 | 0.0282 |
Node | 0 | 1+ | 0.51 (0.28–0.93) | 0.0281 | 0.0281 |
Tumor grade | 1 | 2 | 0.9 (0.37–2.21) | 0.8189 | 0.2003 |
1 | 3 | 0.54 (0.23–1.29) | 0.1684 | ||
Estrogen receptor | Negative | Positive | 2.25 (1.26–4.04) | 0.0064 | 0.0064 |
Progesterone receptor | Negative | Positive | 1.36 (0.75–2.45) | 0.3119 | 0.3119 |
HER2–neu receptor | Negative | Positive | 1.09 (0.52–2.29) | 0.8262 | 0.8262 |
p53 mutation status | Negative | Positive | 0.73 (0.36–1.51) | 0.4000 | 0.4000 |
EGFR | 1 | 2 | 0.79 (0.11–5.66) | 0.8180 | 0.0013 |
1 | 3 | 0.96 (0.13–6.95) | 0.9712 | ||
1 | 4 | 9.64 (1.63–56.92) | 0.0124 | ||
EGFR | 1/2 | 3/4 | 4.46 (1.42–14.01) | 0.0106 | 0.0106 |
CK 5/6 | 1/2 | 3/4 | 0.54 (0.15–1.88) | 0.3333 | 0.3333 |
CD31 | ≤39.5 | >39.5 | 0.43 (0.24–0.77) | 0.0041 | 0.0041 |
pAKT473 | 1/2 | 3/4 | 1.87 (0.87–4) | 0.1063 | 0.1063 |
p-caspase 9 | 1/2/3 | 4 | 1.89 (1.08–3.31) | 0.0263 | 0.0263 |
NOS2 | 1/2/3 | 4 | 2.22 (1.26–3.92) | 0.0057 | 0.0057 |
COX2 | 1/2 | 3/4 | 2.14 (1.2–3.83) | 0.0100 | 0.0100 |
(1) Specific-level p value, (2) overall variable p value
Bold values indicate statistical significance p < 0.05